Clinical Trial Update: CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on CFI-402257 in combination with paclitaxel for advanced/metastatic HER2-negative breast cancer (Phase 1/Phase 2). Results were posted on…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CFI-402257
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Canadian Cancer Trials Group | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-06-26